PBMs Take Aim At Disclosure, Transparency Provisions In House Health Reform Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
CVS Caremark CEO Tom Ryan predicts during the company's second quarter call that "once CBO scores this, [the transparency provision] will not survive."
You may also be interested in...
PBM Disclosure Requirements On Rx Switches Likely To Increase Costs – FTC
Pharmaceutical benefit manager disclosure requirements related to drug switches are likely to increase consumers' drug costs rather than strengthen consumer protections, the Federal Trade Commission said in its review of PBM transparency legislation under consideration in California
Medicare PBM Restrictions Would Lead To Higher Premiums, CBO Says
The PBM "transparency" provision in the Senate's Medicare prescription drug bill would lead to higher monthly premiums and higher beneficiary cost-sharing, the Congressional Budget Office said
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.